Business Wire

HYTERA

28.3.2022 08:02:10 CEST | Business Wire | Press release

Share
Hytera Announces Global Launch of Next Gen DMR Radio Terminals: H Series

Hytera (SZSE: 002583), the global leading provider of professional communications equipment and solutions, is delighted to announce the launch of its next generation H Series of DMR terminals, designed to meet and exceed the increasingly complex and demanding communication challenges facing public safety, energy, transportation, utilities, commercial and other industry verticals.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005001/en/

Built for Customer Success

The newly developed hardware platform and software architecture delivers improved radio performance and optimises the user experience to provide more intuitive, practical, and easy to use functionality. This allows users to focus on the task in hand and provide better, safer and more efficient outcomes for the organisations and communities they serve.

Lighter, Slimmer and More Powerful

The new hand portables comprise the HP7 Series (HP78X/HP70X) and the HP6 Series (HP68X/HP60X) radios. They are more compact, lighter and deliver increased battery capacity and battery life. The radios provide enhanced audio clarity and loudness thanks to a combination of high-performance speakers and DSP algorithm, while embedded AI noise cancellation makes the audio even clearer.

Impressive New Features

Other innovations include using the vibration of the speaker to expel water through a specially designed cavity to ensure clear audio even in torrential weather. Direct mode communication range is extended by 25% in open environments, while signal quality is improved at the edge of the network when in trunking mode.

The HM78X mobile radio delivers similar performance enhancements as the portable terminals. New highlights include an optimised control head-mounting solution that supports flexible deployment options. The inclusion of an Ethernet port allows the radio to function as a gateway for narrowband networking, while also supporting the easy addition of new features from third-party companies and platforms.

The HR106X compact digital repeater completes the latest line-up. Despite being half the size of its predecessor, Hytera has managed to integrate a telephone gateway, router and power adapter inside this versatile repeater to provide an all-in-one solution.

Hytera users depend on the ingenuity and advancement that only Hytera can deliver, to help them carry out the most demanding tasks in challenging environments. Hytera’s H Series solutions are designed for optimum performance that is more powerful, more capable and even easier to use than ever before, enabling users to respond and achieve.

Hytera held its global online launch event on March 24th during which it introduced and demonstrated the brand-new H Series and business radio series AP/BP. It also shared insights on PMR industry trends and expertise on professional communications at the event.

Watch the recorded event here: https://bit.ly/3urgQfg

Link:

ClickThru

Social Media:

https://www.facebook.com/Hytera.Global

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye